Clinical Trial Update: Unmitigated Aldosterone Signaling During Standard Clinical MRA Dosing [Phase 4]

View source ↗

Summary

A Phase 4 trial at Yale University is evaluating unmitigated aldosterone signaling during standard mineralocorticoid receptor antagonist dosing in heart failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Snippet

Sponsor: Yale University | Conditions: Heart Failure | Phase 4 | Status: RECRUITING